Announcements Trials

Browse Landscape

Phase

Phase 2 4 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Recurrence 2 Neoplasm Metastasis 1 Lung Neoplasms 1

Interventions

pembrolizumab 37 Carboplatin 26 Radiotherapy 23 Cisplatin 19 Paclitaxel 18 Erlotinib Hydrochloride 18 Docetaxel 15 Gemcitabine 14 Pemetrexed 13 Etoposide 12 osimertinib 11 Nivolumab 11 durvalumab 9 atezolizumab 9 Radiosurgery 8 Magnetic Resonance Spectroscopy 8 Cetuximab 7 Specimen Handling 6 Cyclophosphamide 6 130-nm albumin-bound paclitaxel 6 Taxes 5 Immunoglobulin G 5 Gefitinib 5 Biopsy 5 Bevacizumab 5 fludarabine 4 Radiation 4 Ipilimumab 4 Disulfides 4 Albumin-Bound Paclitaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lung Neoplasms × lorlatinib × Clear all

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡